Amylyx Pharmaceuticals, Inc. (also referred to as Amylyx, we, our or us) is a clinical-stage pharmaceutical company with a mission to develop and advance novel therapies for communities with high unmet medical needs. We have preclinical and clinical development programs underway in endocrine conditions and neurodegenerative diseases.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (FY)
$0.00
▼ -100.0% YoY
Net Income (TTM)
-$152M
▲ +52.0% YoY
Op. Margin
–
ROIC
-43.69%
▲ +31.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$127M
▲ +26.4% YoY
Op. Cash Flow (TTM)
-$127M
▲ +26.4% YoY
Net Debt
-$246M
Net Cash Position
Cash & Equiv.
$251M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with AMLX
Held by ETFs
AMLX is in 45 US ETFs. The largest of them, with AMLX's weight in each:
Amylyx Pharmaceuticals (AMLX) in three numbers
Questions about Amylyx Pharmaceuticals
Is Amylyx Pharmaceuticals a high-quality business?
Amylyx Pharmaceuticals scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from SEC filings. Its best check is net debt at -$246M, and its weakest is return on capital at -43.7%. The Quality tab shows every check against its target.
Does Amylyx Pharmaceuticals (AMLX) pay a dividend?
No. Amylyx Pharmaceuticals (AMLX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 27 Jul 2026 (period ending 30 Jun 2026), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in AMLX's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing AMLX
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.